REFERENCES
- Yau J. C., Yap Y. Y., Buzdar A. U., Hortobagyi G. N., Bodey G. P., Blumenschein G. R. A Comparative Randomized Trial of Vinca Alkaloids in Patients with Metastatic Breast Carcinoma. Cancer 1985; 55: 337–340
- Lu K., Yap H. Y., Loo T. L. Clinical Pharmacokinetics of Vinblastine by Continuous Intravenous Infusion. Cancer Res. 1983; 43: 1405–1408
- Valeriote F. A., Bruce W. R., Meeker B. E. A Model for the Action of Vinblastine In Vivo. Biophys. J. 1966; 6: 145–152
- Johnson I. S., Armstron J. G., Gorman M., Burnett J. P., Jr. The Vinca Alkaloids: A New Class of Oncolytic Agents. Cancer Res. 1963; 23: 1390–1427
- Jackson D. V. The Periwinkle Alkaloids. Cancer Chemotherapy by Infusion, J. J. Lokich. Precept, Chicago 1990; 155–175
- Fraschini G., Yap H. Y., Hortobagyi G. N., Buzdar A., Blumenschein G. R. Five-Day Continuous-Infusion Vin-blastine in the Treatment of Breast Cancer. Cancer 1985; 56: 225–229
- Johnson S. A., Harper P., Hortobagyi G. N., Pouillart P. Vinorelbine: An Overview. Cancer Treat. Rev. 1996; 22: 127–142
- Toussaint C., Izzo J., Spielmann M., Merle S., May-Levin F., Armand J. P., Lacombe D., Tursz T., Sunderland M., Chabot G. G., Cvitkovic E. Phase I/II Trialof Continuous Infusion Vinorelbine for Advanced Breast Cancer. J. Clin. Oncol. 1994; 12: 2102–2112
- Rahmani R., Martin M., Barbet J., Cano J. P. Radioimmunoassay and Preliminary Pharmacokinetic Studies in Rats of 5′-Noranhydrovinblastine (Navelbine). Cancer Res. 1984; 44: 5609–5613
- Rahmani R., Bruno R., Iliadis A., Favre R., Just S., Barbet J., Cano J-P. Clinical Pharmacokinetics of the Antitumor Drug Navelbine (5′-noranhydrovinblastine). Cancer Res. 1987; 13: 2722–2730
- Hoff P. M., Valero V., Ibrahim N., Willey J., Hortobagyi G. N. Hand-Foot Syndrome Following Prolonged Infusion of High Doses of Vinorelbine. Cancer 1998; 82: 965–969
- Canobbio L., Boccardo F., Pastorino G., Brema F., Martini C., Resasco M., Santi L. Phase II Study of Navelbine in Advanced Breast Cancer. Semin. Oncol. 1989; 16: 33–36
- Fumoleau P., Delgado F. M., Delozier T., Monnier A., Gil Delgado M. A., Kerbrat P., Garcia-Giralt E., Keiling R., Namer M., Closon M. T., Goudier M. J., Chollet P., Lecourt L., Montcuquet P. Phase II Trial of Weekly Intravenous Vinorelbine in First Line Advanced Breast Cancer Chemotherapy. J. Clin. Oncol. 1999; 11: 1245–1252
- Weber B. L., Vogel C., Jones S., Harvey H., Hutchins L., Bigley J., Hohneker J. Intravenous Vinorelbine as First Line and Second Line Therapy inAdvanced Breast Cancer. J. Clin. Oncol. 1995; 13: 2722–2730
- Romero A., Rabinovich M. G., Vallejo C. T., Perez J. E., Rodriguez R., Cuevas M. A., Machiavelli M., Lacava J. A., Langhi M., Romero Acuna L., Amato S., Barbieri R., Sabatini C., Leone B. A. Vinorelbine as First-Line Chemotherapy for Metastatic Breast Carcinoma. J. Clin. Oncol. 1994; 12: 336–341
- Jones S., Winer E., Vogel C., Laufman L., Hutchins L., O'Rourke M., Lembersky B., Budman D., Bigley J., Hohneker J. A Randomized Comparison of Vinorelbine and Melphalan in Anthracycline-Refractory Advanced Breast Cancer. J. Clin. Oncol. 1995; 13: 2567–2574
- Livingston R. B., Ellis G. K., Gralow J. R., Williams M. A., White R., McGuirt C., Adamkiewicz B. B., Long C. A. Dose-Intensive Vinorelbine with Concurrent Colony Stimulating Factor Support in Paclitaxel-Refractory Metastatic Breast Cancer. J. Clin. Oncol. 1997; 15: 1395–1400